Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
OwnerGary Sieckman, Wynn Volkert +3inventors
InventorsGary Sieckman, Wynn Volkert, Leonard Forte, Timothy Hoffman, Hariprasad Gali
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of targeting breast cancer, prostate cancer, pancreatic cancer or melanoma cells using ST peptides. These methods permit both diagnostic evaluation and therapeutic intervention using appropriate conjugates.
Claims69
A method for targeting an agent to a breast cancer cell, a prostate cancer cell, a pancreatic cancer cell or a melanoma cancer cell comprising bringing said cancer cell into contact with a peptide-agent complex, wherein said peptide comprises an ST motif that binds to breast cancer cells, prostate cancer cells, pancreatic cancer cells or melanoma cancer cells.
A method for diagnosing breast cancer, prostate cancer, pancreatic cancer or melanoma in a subject comprising:
- (a) administering to said subject a peptide-diagnostic agent complex, wherein said peptide comprises an ST motif, wherein said ST motif binds to breast cancer cells, prostate cancer cells, pancreatic cancer cells or melanoma cancer cells;
- and
- (b) assessing the amount and/or localization in said subject, of the diagnostic agent.
A method for treating breast cancer, prostate cancer, pancreatic cancer or melanoma in a subject in need thereof comprising administering to said subject a peptide-therapeutic agent complex, wherein said peptide comprises an ST motif and binds to breast cancer cells, prostate cancer cells, pancreatic cancer cells or melanoma cancer cells.
A method for rendering an unresectable breast, prostate, pancreatic or melanoma tumor resectable comprising administering to a subject having said tumor a peptide-therapeutic agent complex, wherein said peptide comprises an ST motif that binds to breast cancer cells, prostate cancer cells, pancreatic cancer cells or melanoma cancer cells.
A method for treating metastatic breast cancer, prostate cancer, pancreatic cancer or melanoma comprising administering to a subject in need thereof a peptide-therapeutic agent complex, wherein said peptide comprises an ST motif that binds to breast cancer cells, prostate cancer cells, pancreatic cancer cells or melanoma cancer cells.
A method for preventing recurrent breast cancer, prostate cancer, pancreatic cancer or melanoma comprising administering to a subject having been successfully treated for breast cancer, prostate cancer, pancreatic cancer or melanoma a peptide-therapeutic agent complex, wherein said peptide comprises an ST motif that binds to breast cancer cells, prostate cancer cells, pancreatic cancer cells or melanoma cancer cells.
A method for identifying tumor binding peptides comprising:
- (a) providing a breast cancer cell, a prostate cancer cell, a pancreatic cancer cell or a melanoma cell;
- (b) contacting said cell, in the presence of a candidate peptide, with a labeled, tumor-binding ST peptide that binds to breast cancer cells, prostate cancer cells, pancreatic cancer cells or melanoma cancer cells;
- (c) measuring the association of label with said cell, as compared to the association of label with said cell in the absence of said candidate peptide;
- and
- (d) measuring binding of said candidate peptide to ST peptide, wherein a decrease in association of label with said cell, and the absence of candidate peptide binding to ST peptide, indicates that said candidate peptide is competing with ST peptide for tumor cell binding.
Dependencies are inferred from the claim text.